Activation of lymphocytes induces blastogenesis and cell division which is accompanied by membrane lipid metabolism such as increased fatty acid turnover. To date little is known about the enzymatic mechanism(s) regulating this process. Release of fatty acids such as arachidonic acid requires sn-2-deacylation catalyzed by a class of enzymes known as phospholipases A 2 (PLA 2 , EC 3.1.1.4). Herein, we confirm that human peripheral blood B or T lymphocytes (PBL) do not possess measurable levels of 85-kDa PLA 2 as assessed by Western immunoblot. Low levels of 14-kDa PLA 2 protein and activity were detectable in the particulate fraction of PBL and Jurkat cells. Western immunoblot analysis indicates that PBLs possess the calcium-independent PLA 2 (iPLA 2 ) protein. Calcium-independent sn-2-acylhydrolytic activity was measurable in PBL cytosols and could be inhibited by the selective iPLA 2 inhibitor bromoenol lactone. Mitogen activation of PBLs resulted in maintenance of activity levels which remained constant over 72 h suggesting an important role for iPLA 2 in this proliferative process. Indeed, evaluation of iPLA 2 activity in cell cycle-arrested Jurkat T cell fractions revealed the highest iPLA 2 levels occurring at the G 2 /M phase. Addition of the iPLA 2 inhibitors, bromoenol lactone, or arachidonyl trifluoromethyl ketone (AAOCF 3 ), inhibited both mitogen-induced PBL as well as Jurkat T cell proliferation. Moreover, specific depletion of iPLA 2 protein by antisense treatment also resulted in marked suppression of cell division. Inhibition of Jurkat cell proliferation was not associated with arrest at a particular phase of the cell cycle nor was it associated with apoptosis as assessed by flow cytometry. These findings provide the first evidence that iPLA 2 plays a key role in the lymphocyte proliferative response.
Activation of resting lymphocytes occurs by ligation of antigen-specific co-receptors or artificially through mitogen stimulation. This in turn results in the formation of blast cells which undergo cellular proliferation, differentiation, and clonal expansion. Preparation for cell division requires not only synthesis of nucleotide pools and new protein but also increases in phospholipid (PL) 1 content and remodeling of existing PL in support of new membrane formation (1) . Several studies have demonstrated that changes in membrane PL (1, 2) and arachidonic acid (AA) metabolism (3, 4) occur during the cell cycle. More specifically, mitogen activation of lymphocytes is accompanied by an increase in fatty acid turnover and an enrichment of PL with AA, the major substrate of proinflammatory eicosanoids (3) (4) (5) (6) . The AA comes from internal pools since the enrichment occurs in serum-free conditions (3, 4) . The fact that this phenomenon, requiring deacylation-reacylation of PL, is AA specific and targeted toward selected PL classes (e.g. phosphatidylethanolamine and phosphatidylinositol) suggests regulation through specific enzyme systems (4) . Indeed, the lysophosphatide acyltransferase, a reacylating enzyme, preferentially incorporates polyunsaturated fatty acid (i.e. AA) into membrane PL. The molecular mechanism regulating these events is not fully elucidated. It is conceivable that the family of enzymes which catalyze the acylhydrolysis of fatty acid from the sn-2 position of membrane PL, namely the phospholipase(s) A 2 (PLA 2 ) would be important.
The two best characterized mammalian PLA 2 enzymes, are the calcium-dependent 14-kDa PLA 2 (types IIa, V and X) and 85-kDa PLA 2 (type IV) (7) . The 14-kDa PLA 2 (s) exist as extracellular forms in inflammatory fluids (8, 9) and in a cell-associated form (10 -13) and requires calcium for catalysis. The cytosolic 85-kDa PLA 2 is structurally distinct and unlike the 14-kDa PLA 2 (s) exhibits a preference for AA in the sn-2 position of PL and is regulated by physiological intracellular Ca 2ϩ concentrations and phosphorylation (14 -16) . We and others have shown that both the 14-and 85-kDa enzymes are induced by inflammatory cytokines and growth factors (17) (18) (19) (20) and that both enzymes influence cellular AA release and subsequent eicosanoid production in a variety of cell types (17, (21) (22) (23) (24) . More recently, a calcium-independent PLA 2 (iPLA 2 ) has been cloned from Chinese hamster ovary cells, murine P388D1 macrophages, and a human B cell line (25) (26) (27) . Although little data exists regarding its function, antisense depletion of the murine iPLA 2 caused inhibition of AA incorporation into membrane PL with or without stimulation but did not affect receptor-coupled arachidonate mobilization suggesting a housekeeping role for this enzyme in basal PL remodeling in P388D1 macrophages (28) . Conversely, studies by Ramanadham and co-workers (29) demonstrated the lack of a role for iPLA 2 in islet cell remodeling.
The potential contribution of these distinct enzymes in regulating cellular proliferation has only begun to be examined. The prevalence of these three enzymes in B or T lymphocyte populations is still under investigation and their potential involvement in lymphocyte proliferative processes is not known. * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
‡ To whom correspondence should be addressed: Dept. of Immunology, SmithKline Beecham Pharmaceuticals, 709 Swedeland Rd., King of Prussia, PA 19406. Tel.: 610-270-4969; Fax: 610-270-5381. 1 The abbreviations used are: PL, phospholipid; AA, arachidonic acid; PLA 2 , phospholipase A2; BEL, bromoenol lactone; iPLA 2 , calcium-independent phospholipase A 2 ; ELISA, enzyme-linked immunosorbent assay; PHA, phytohemagglutinin; PBL, peripheral blood B or T lympho-Herein, we assess the presence of the PLA 2 isoforms in purified human monocytes, B cells and T cells and/or in Jurkat T cells through enzymatic assays, ELISA, and Western analysis. We demonstrate the presence of iPLA 2 in peripheral blood B and T cells and the Jurkat T leukemia cell line. We then evaluate both the effects of isoform selective PLA 2 inhibitors as well as antisense technology on Jurkat and mitogen-induced (phytohemagglutinin; PHA) PBL proliferation and cell cycle progression. Both iPLA 2 inhibition and depletion of iPLA 2 protein using antisense demonstrates that this enzyme plays a key role in lymphocyte proliferation.
EXPERIMENTAL PROCEDURES

Cell Isolation and Culture
Mixed Lymphocyte Isolation-Human monocyte-depleted peripheral blood lymphocytes were isolated from whole blood as described previously (30) . The resultant population was greater than 85% pure lymphocytes as assessed by differential staining. Cells were resuspended to 2 ϫ 10 6 /ml and cultured in RPMI 1640 with 10% fetal bovine serum unless otherwise noted.
Purification of Human Monocytes, B or T Lymphocytes-Human peripheral blood leukocytes (buffy coat) were isolated from whole blood as described previously and a greater than 95% pure population of human monocytes was obtained by separation over a Ficoll gradient followed by adherence (2 h) as described previously (12, 23) . Purified B cells from human spleen were isolated through positive immunomagnetic selection using magnetic polystyrene beads coated with monoclonal antibody to the B cell-restricted membrane antigen, CD19 (Dynabeads M-450 Pan-B (CD19), Dynal Lake Success, NY) as described previously (30) . Purified human peripheral blood T lymphocytes were obtained by separation over T cell enrichment columns, HTCC (R & D Systems, Minneapolis, MN), as per the manufacturer's instructions. The Jurkat T cell leukemia was acquired from American Type Culture Collection (Rockville, MD). The cells were maintained at a density of 1 to 5 ϫ 10 5 cells/ml and grown as suspension cultures in RPMI 1640 with 2 mM L-glutamine, 1.5 g/liter NaHCO 3 , and 10% fetal bovine serum.
Chemical Cell Cycle Arrest and FACS Analysis of Jurkat T Lymphocytes
Cells were chemically arrested at G 1 /S, S, or G 2 /M using established protocols (31) . Jurkat cells at 5 ϫ 10 5 /ml were treated with either 3 mM hydroxyurea for 16 h to give a G 1 /S phase arrest or 0.1 g/ml nocodazole for 12 h to achieve a G 2 /M phase arrest. In addition, cells were also treated with 2 mM thymidine for 17 h, released for 6 h in culture media (no thymidine), then retreated with 2 mM thymidine for 15 h to allow for a broad S-phase arrest. The specific cell cycle phase arrest of the individual populations was verified by measuring the fluorescence intensities using a Becton-Dickinson FACSTAR Plus. Briefly, following the treatments, the cells were centrifuged, the media was removed, and the cells were resuspended in 750 l of ice-cold phosphate-buffered saline. To fix the cells, 2 ml of 95% ethanol (Ϫ20°C) was added and cells were then washed twice with 2 ml of phosphate-buffered saline and resuspended in 1 ml of a solution containing 250 g/ml propidium iodide and 250 g/ml RNase A. The stained cells were vortexed, then incubated at room temperature for 1 h in darkness prior to FACS evaluation of cell cycle phase. Forward scatter versus side light scatter and fluorescent area versus width were used to gate for intact, single cells. Results were based on 20,000 gated cell events.
Subcellular Fractionation
Cell pellets were resuspended to 1 ϫ 10 8 cells/0.5 ml in homogenization buffer containing 0.34 M sucrose, 10 mM HEPES, pH 7.4, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 200 M leupeptin, 20 g/ml soybean trypsin inhibitor, and 20 g/ml aprotinin at 4°C. The cell suspension was disrupted on ice by sonication (5 s) with a Bransonic probe tip and the homogenate was centrifuged at 400 ϫ g for 10 min at 4°C to remove unbroken cells and debris. The resulting supernatant fraction was centrifuged at 100,000 ϫ g for 60 min at 4°C to obtain a supernatant (cytosol) and particulate fraction. The particulate fraction was resuspended in homogenization buffer and both fractions were flash frozen with liquid N 2 and stored at Ϫ80°C until analysis.
ELISA Analysis of Type II 14-kDa PLA 2 Cell fractions were assessed for 14-kDa PLA 2 mass using a specific enzyme-linked immunosorbent assay as described previously (22) . This ELISA recognizes both the Type IIa and Type V 14-kDa PLA 2 but not the Type X 14-kDa PLA 2 .
Immunoblot Analysis
Cell cytosols (50 -100 g of protein) were analyzed by SDS-polyacrylamide gel electrophoresis (10% Tris glycine gels, Bio-Rad). Proteins were transferred to nitrocellulose paper, incubated with either rabbit anti-rh 85-kDa PLA 2 antiserum (1:500) or rabbit anti-iPLA 2 antiserum (1:500; Caymen Chemical) and then incubated with donkey anti-rabbit IgG conjugated to horseradish peroxidase (1:3000; Roche Molecular Biochemicals, Indianapolis, IN). Detection of immunoreactive bands was carried out using the ECL Western blotting system (Amersham Pharmacia Biotech). Rabbit polyclonal antiserum against the rh 85-kDa PLA 2 was prepared as described previously (23) .
Phospholipase A 2 Enzyme Assays
Calcium-dependent PLA 2 activity was routinely measured by the acylhydrolysis of [ 3 H]AA Escherichia coli as described previously (12) . Briefly, the reaction mixture (50 l total volume) contained 25 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM CaCl 2 , and 100 M [ 3 H]AA-labeled E. coli (5 nmol of lipid phosphorus (P i ) per assay. The assay was initiated by addition of substrate and assays were incubated at 37°C for a time predetermined to be on the linear portion of a time versus hydrolysis plot. Calcium-independent PLA 2 activity was measured by the acylhydrolysis of a Triton X-100 (400 M), 1-palmitoyl-2-[1-
14 C]arachidonyl-sn-glycero-3-phosphorylcholine (50 M; 56 Ci/mol; Amersham Pharmacia Biotech) mixed micelle according to published methods (26) . In addition to the substrate, the reaction mixture contained 100 g of cell fraction, 100 mM HEPES, pH 7.5, 5 mM EDTA, and 1 mM ATP. The reaction was initiated by the addition of substrate and allowed to proceed at 37°C for 60 min. Dimethyl sulfoxide (Me 2 SO) vehicle or drug was added as no greater than 10% of the total assay volume. All drugs or vehicle were added 10 min prior to substrate addition unless otherwise stated. Both reactions were terminated by the addition of 1.0 ml of tetrahydrofuran. Free fatty acid was exclusively separated by elution of the sample over aminopropyl solid phase silica columns with tetrahydrofuran/acetic acid (49:1) and quantitated by liquid scintillation counting as described previously (12) .
Cellular Proliferation
Human PBL or Jurkat T cells were resuspended to 2 ϫ 10 6 cells/ml in RPMI 1640 with 10% fetal bovine serum and 200 l of the suspension was added to each well of a Nunc 96-well cell culture plate. Drug or Me 2 SO vehicle (0.05%) was added to cells for 15 min at 27°C prior to the addition of PHA (30 g/ml for PBL cultures) and incubation for 72 h at 37°C in a 5% CO 2 incubator. [ 3 H]Thymidine (PerkinElmer Life Sciences, Wilmington, DE) was diluted in RPMI 1640 and 0.1 Ci/well was added to the cells for 6 h prior to harvesting. Plates were harvested using a Packard Filtermate 196 cell harvester onto Packard Unifilter GF/C filter plates. Scintillation fluid was added and filters were quantitated using a Packard Topcount Microplate counter. For antisense studies, PBLs were exposed to initiation site-directed antisense phosphorothioate oligonucleotides SB8603 (5Ј-aaggcgtccgaactgcat-3Ј) or SB 8604 (5Ј-aaggcggccaaggaactgcat-3Ј), a scrambled control oligonucleotide, SB8606 (5Ј-cggggaggacgctagacgatc-3Ј), an unrelated control oligonucleotide SB9030 (tccgaaggcagaaaggcttca-3Ј) or LipofectAMINE vehicle alone (5 g/ml) for 24 h at 37°C prior to stimulation with PHA (30 g/ml) for an additional 72 h. Cell viability was monitored using either trypan blue exclusion or the Cytotox 96 Assay System (Promega, Madison, WI) for all studies.
Apoptosis Measurement
Apoptosis was measured by TUNEL (32) using the Promega ApopTag kit (Madison, WI) as per the manufacturer's directions. In brief, the enzyme terminal deoxynucleotidyl transferase extends the DNA fragments with digoxigenin-containing nucleotides, which are then detected with a anti-digoxigenin antibody carrying fluorescein to allow detection by fluorescence (494 nm excitation, 523 nm emission). Propidium iodide was used as a counterstain to measure total DNA content and determine distribution of cells in G 0 /G 1 , S, and G 2 /M phases of the cell cycle. Flow cytometric analysis was performed on a Becton-Dickinson FACScan instrument using CellQuest software.
Protein Determination
All protein concentrations were determined by Bradford protein analysis kits (Bio-Rad).
Calculations and Statistics
Data are expressed as mean Ϯ S.D. of triplicate determinations unless otherwise stated. All experiments were conducted 2-4 times using cells obtained from different donors.
RESULTS
Evaluation of 14-kDa, 85-kDa, and Calcium-independent PLA 2 Isoform Protein Levels in Human Monocytes, B Lymphocytes, and T Lymphocytes-
We have previously demonstrated the presence of 14-kDa PLA 2 protein in isolated human monocytes (22) . Human PBL cytosolic and particulate fractions were evaluated for 14-kDa PLA 2 by ELISA. Particulate fractions contained low but detectable levels of 14-kDa PLA 2 (1.4 ng of 14-kDa PLA 2 /300 g of total PBL particulate protein) while no immunoreactive protein was detectable in the cytosolic fraction. Jurkat T cell particulate fractions contained 0.5 g of 14-kDa PLA 2 /300 g of total particulate protein. RT-PCR analysis of Jurkat RNA for type IIa and type V 14-kDa PLA 2 indicated the existence of only the type V isoform (data not shown).
85-kDa PLA 2 and iPLA 2 levels were evaluated in the subcellular fractions of purified CD19 ϩ B lymphocytes, CD4 ϩ T lymphocytes, and peripheral blood monocytes as described under "Experimental Procedures." The cytosolic fractions (100 g/ lane) were separated by SDS-polyacrylamide gel electrophoresis and immunoblotted using either a rabbit anti-human 85-kDa PLA 2 polyclonal antisera or a rabbit anti-hamster iPLA 2 polyclonal antisera which cross-reacts with human. Fig. 1A shows a Western analysis of 85-kDa PLA 2 protein levels where a 110-kDa immunoreactive band is clearly present in human monocytes as has been previously described (23) . However, an appropriately sized immunoreactive protein is not detectable in purified T or B lymphocytes. Calcium-independent PLA 2 immunoreactive protein (ϳ80 -85 kDa) was present in the cytosolic fraction of both purified peripheral blood B and T cells but it was not detectable in human monocytes cytosols (Fig. 1B) .
Evaluation of PLA 2 Acylhydrolytic Activity in PBL and Jurkat T Cells-PBL were next examined for calcium-independent sn-2 acylhydrolytic activity using a Triton X-100 phosphatidylcholine-mixed micelle substrate as has been previously described (25, 26) . Cells were incubated for 0 -72 h in the absence or presence of the T cell-specific mitogen, PHA (30 g/ml), prior to preparation of subcellular fractions. (Fig. 2B) . In a second study, calcium-independent activity was measured in the cytosol and was shown to be completely inhibited by addition of the iPLA 2 inhibitor, bromoenol lactone (BEL), (control, 113 Ϯ 10.0 pmol/ min/mg; 10 M BEL, 0.5 Ϯ 0.2 pmol/min/mg).
The Jurkat cell line is a transformed, immortalized T cell line and as such does not require activation to induce proliferation. RT-PCR analysis of Jurkat mRNA was first performed and indicated the presence of iPLA 2 message (data not shown). These cells were chemically synchronized at G 1 /S, S, or G 2 /M phase of the cell cycle, collected, and fractionated as described under "Experimental Procedures." The fractions were analyzed for either calcium-dependent (14-kDa PLA 2 ) or -independent (iPLA 2 ) activity. Recombinant human (rh) type II 14-kDa PLA 2 was used as an assay control and gave a robust signal of 29 mol/mg/min Fig. 3 shows the calciumindependent sn-2 acylhydrolysis measured in the cytosolic fraction of cell cycle phase-arrested Jurkats. As expected, the calcium-dependent rh 14-kDa PLA 2 showed no activity in this assay and served as a negative control. Asynchronous cells possessed measurable calcium independent activity (46 pmol/ mg/h 1-palmitoyl-2-[1-
14 C]arachidonyl-sn-glycero-3-phosphorylcholine mixed micelle hydrolyzed). Enzymatic activity was not significantly different when assessed using the cytosols of cells arrested in G 1 /S or S (35 and 65 pmol/mg/h). However, the cytosols of G 2 /M-arrested cells exhibited 3-4-fold greater calcium independent PLA 2 activity (168 pmol/mg/h).
Effect of Phospholipase A 2 Inhibitors on Jurkat T Cell and PHA-induced Human Lymphocyte Proliferation-
The transition state inhibitor, arachidonyl trifluoromethyl ketone, AAOCF 3 (IC 50 versus recombinant human 85-kDa PLA 2 , 100 nM; IC 50 versus semi-purified iPLA 2 , 15 M (22, 33)), the iPLA 2 inhibitor, BEL (IC 50 P388D iPLA 2 ; 60 nM (33)), and the 14-kDa PLA 2 selective inhibitor SB203347 (IC 50 versus rh 14-kDa PLA 2 , 500 nM (34)) were evaluated for their effect on PHAinduced human PBL proliferation. Isolated PBL were exposed to increasing concentrations of AAOCF 3 , BEL, or SB203347 (10 -30 M) or Me 2 SO vehicle alone (0.05%) for 15 min prior to the addition of PHA (30 g/ml) for 72 h. Proliferation was measured by [ 3 H]thymidine incorporation as described under "Experimental Procedures." Fig. 4 shows one representative of three studies where treatment with either AAOCF 3 or BEL caused a concentration-dependent inhibition of PHA-induced proliferation. Pretreatment with the 14-kDa PLA 2 inhibitor, SB203347, however, had no effect on lymphocyte proliferation induced by PHA.
To further delineate the mechanism of PLA 2 action in PHAinduced PBL proliferation, cells were cultured in the presence of AAOCF 3 (15 M), BEL (15 M), or indomethacin (1 M) in the presence or absence of exogenous AA (20 M). Fig. 5 confirms the inhibition of proliferation by AAOCF 3 and BEL. However, treatment with the cycloxygenase inhibitor, indomethacin, did not significantly effect tritiated thymidine uptake in the presence or absence of exogenous AA (20 M), suggesting the antiproliferative effect of the PLA 2 inhibitors is likely not due to alterations in prostanoid production in the cell culture. Similarly, addition of exogenous AA did not reverse the inhibition PLA 2 inhibitor, SB203347, had no significant effect compared with untreated control cells. Flow cytometric analysis using propidium iodide and TUNEL staining indicated that inhibition of proliferation by either BEL or AAOCF 3 was not associated with an arrest at a specific cell cycle phase nor was it accompanied by apoptosis over 72 h (data not shown). Cytosolic fractions of Jurkat T cells arrested in G 2 /M were prepared as described under "Experimental Procedures" as they have previously been shown to possess the highest amount of iPLA 2 activity (Fig. 3) . This fraction was incubated with or without 10 M BEL for 15 min, prior to evaluation of iPLA 2 enzymatic activity. BEL inhibited activity in this fraction by 50% (Fig. 6B) Effect of iPLA 2 Antisense on PHA-induced PBL Proliferation-An antisense phosphorothioate oligonucleotide directed against the initiation site of the human iPLA 2 was synthesized in order to directly evaluate the contribution of the enzyme in PHA-induced PBL proliferation. Fig. 7A shows a Western blot analysis of cytosols (50 g/lane) from PBL treated with either Lipofectin vehicle alone, SB8603 (3 M), SB8604 (3 M), or SB9030 (3 M) for 24 h prior to addition of PHA and incubation for an additional 72 h. Treatment with PHA maintained iPLA 2 protein levels which is consistent with increased activity observed in Fig. 2 using cells from a different donor. Addition of either antisense SB8603 or SB8604 but not the control oligonucleotide, SB9030, caused a marked reduction in the level of iPLA 2 immunoreactive protein when compared with the PHAstimulated control cytosols. PBL were pretreated with either antisense oligonucleotides SB8603 or SB8604 (0.3 or 3 M), the control oligonucleotide, SB9030 (0.3 or 3 M), or Lipofectin vehicle alone (5 g/ml) for 24 h prior to exposure to PHA (30 g/ml). Cells were pulsed with [ 3 H]thymidine (0.1 Ci) at 66 h and thymidine incorporation was quantitated at 72 h. Fig. 7B shows that pretreatment with either SB8603 or SB8604 caused a significant concentration-dependent inhibition of the PHA induced PBL proliferative response. In contrast, exposure to the control oligonucleotide, SB9030, did not effect thymidine incorporation over 72 h when compared with the vehicle control. Similar results were obtained in a second study (unstimulated Lipofectin control: 2,137 Ϯ 517 cpm; PHA stimulated 
DISCUSSION
Lipid metabolism is an integral process of immune cell blast formation and proliferation. In the present study, we show that both freshly isolated T and B lymphocytes and cell lines (e.g. Jurkat T leukemia cells) possess low levels of Ca 2ϩ -dependent PLA 2 activity but are devoid of 85-kDa PLA 2 protein. Moreover, we show for the first time, that these three cell types possess Ca 2ϩ -independent PLA 2 protein and activity and demonstrate that it is this enzyme which appears to be critical for lymphocyte proliferation.
Consistent with recent reports, Western analysis of peripheral blood T and B lymphocyte cytosols confirmed the lack of the 85-kDa PLA 2 protein in these cells. The existence of 85-kDa PLA 2 mRNA and protein has been reported in activated thymocytes and immature B cells, but it is not present and its expression cannot be induced in mature B or T cells or several lines suggesting a maturation-specific phenomenon (35) . The type IIa 14-kDa PLA 2 mRNA is found in lymphoid tissue, such as human tonsil (8) and spleen (17) , and protein has been demonstrated in a number of cell lines including platelets and neutrophils. However, its existence in purified B and T lym- phocytes has not been described. More recently, a second 14-kDa PLA 2 , type V, has been identified in mast cells and the P388D1 murine macrophage cell line but a detailed analysis of its expression in human lymphocytes has not been conducted (36, 37) . In the present study, ELISA analysis of PBL and Jurkat particulate fractions showed low but detectable levels of a 14-kDa PLA 2 protein. Subsequent RT-PCR analysis demonstrated this to be the type V PLA 2 isoform, a finding which has not been previously reported. Expression of iPLA 2 mRNA was recently reported in human granulocytes and CD34ϩ stem cells as well as the promyelocytic cell line, HL60, and the monoclonal B cell line, Raji (38) . To date, however, no reports exist regarding the occurrence of iPLA 2 mRNA or protein in primary human B or T lymphocytes or human monocytes. We clearly demonstrate the presence of iPLA 2 protein in the cytosol of purified human T and B cells but not in human monocytes.
Enzymatic evaluation of iPLA 2 activity in human PBL and Jurkat T cells revealed proliferation and cell cycle dependent expression. In PBL, exposure to the T cell mitogen, PHA, over 72 h was associated with the maintenance of iPLA 2 protein levels, resulting in activity equal to that observed in freshly isolated cells. Alternatively, the absence of such a stimulus coincided with a decrease in iPLA 2 activity and protein levels. This data indicated a potential requirement for the iPLA 2 enzyme when cells are stimulated to transition from quiesence (G 0 ) to G 1 where proliferative responses are initiated. Interestingly, assessment of iPLA 2 activity in cell cycle arrested Jurkat fractions demonstrated a predominance of activity in the G 2 /M phase arrested fractions which may be due to an increase in protein or an enhanced enzymatic rate. While very little is known about PL metabolism at G 2 /M, this coincides with the reported destruction and reassembly of the nuclear membrane which occurs in cells preparing for mitotic events (1) . As entry and progression through the cell cycle is associated with lipid turnover (2), these data implicate iPLA 2 as having a possible regulatory role in cell division.
To more directly address this hypothesis, two strategies were employed: (a) use of available inhibitors of the various PLA 2 isoforms and (b) utilization of initiation site-directed antisense oligonucleotides. The use of PLA 2 inhibitors has been employed in numerous cell types to investigate the contributions of distinct PLA 2 family members in cellular AA metabolism. The participation of the type IIa 14-kDa PLA 2 in eicosanoid and platelet activating factor production has been investigated in a host of inflammatory cells including monocytes, neutrophils, and mast cells through the use of the structurally distinct 14-kDa PLA 2 inhibitors, e.g. scalardial (21), BMS 181162 (39) , and the active site-directed inhibitor SB 203347 (34) . The transition state inhibitor AAOCF 3 was previously thought to be selective for the 85-kDa PLA 2 (40) but recent studies indicate it also has significant inhibitory activity against the iPLA 2 (33). BEL, a mechanism based inhibitor, is specific for iPLA 2 over both the 14-kDa PLA 2 and 85-kDa PLA 2 (33, 41) and has been successfully used to demonstrate the regulatory role of iPLA 2 in phospholipid metabolism (42) . It should be noted that BEL is also reported to inhibit PA phosphohydrolase (43) . Since no 85-kDa PLA 2 exists in PBL, AAOCF 3 was used as a structurally distinct iPLA 2 inhibitor. Exposure of both PHA-activated PBL or cultured Jurkats to the iPLA 2 inhibitors AAOCF 3 or BEL, but not the 14-kDa PLA 2 inhibitor, SB203347, induced a concentration-dependent suppression of PBL or Jurkat proliferation. Thus, even though 14-kDa PLA 2 Ca 2ϩ dependent activity exists in these cells, these data would indicate that it does not play a significant role in proliferative processes. Alternatively, we demonstrate that inhibition of iPLA 2 activity corresponded with a profound interference of cellular proliferation.
Initiation site-directed antisense has been used to demonstrate the critical role of the 85-kDa PLA 2 in prostanoid formation in systems such as LPS-induced monocyte (22, 23) and IL-1-induced fibroblast PGE 2 production (20) and more recently to demonstrate the requirement for this enzyme in vascular smooth muscle cell proliferation (32) . In addition, iPLA 2 specific antisense has been successfully used to demonstrate the role of this PLA 2 family member in phospholipid fatty acid remodeling in murine P388D1 macrophages (28) . In our studies, exposure of PBL to initiation site-directed iPLA 2 antisense successfully decreased iPLA 2 protein. This correlated with a reduction in proliferation and is consistent with the reduced iPLA 2 protein and activity levels observed in quiescent lymphocytes. These data together with the results from the inhibitor studies provide corroborating evidence implicating the iPLA 2 as a key participant in the molecular processes regulating cell division.
The exact mechanism of iPLA 2 regulation of proliferation is /ml) were exposed to antisense SB8603, SB8604, or control oligonucleotide SB9030 (0.3 or 3.0 M) or Lipofectin alone (5 g/ml) for 24 h. Cells were then exposed to PHA (30 g/ml) for 72 h. [ 3 H]Thymidine (0.1 Ci/well) was added 6 h prior to harvesting and liquid scintillation counting as described under "Experimental Procedures." * indicates significant difference from control values at p Ͻ 0.05. Data represent mean Ϯ S.D., n ϭ 3, of one representative of three studies. not clear. Reports have implicated iPLA 2 in the release of AA for subsequent metabolism to eicosanoids (i.e. leukotrienes and prostaglandins) in other cell systems where proliferation was not assessed (38, 44, 45) . PGE 2 is known to be synthesized upon mitogen stimulation of human PBL. In our hands, pretreatment of mitogen-stimulated PBL with the cyclooxygenase inhibitor, indomethacin which blocks PGE 2 production, had no effect on cell proliferation. Since iPLA 2 has been implicated in free fatty acid generation in other systems, we evaluated the effects of exogenous free fatty acid on PBL proliferation. Addition of free fatty acid alone had no effect on tritiated thymidine incorporation. Interestingly, addition of either AA or oleic acid (data not shown) could not reverse the inhibition obtained by iPLA 2 inhibitors. Taken together the role of iPLA 2 in lymphocyte proliferation appears to be more complex than merely liberation of substrate fatty acids. One possibility is that this PLA 2 family member may orchestrate lymphocyte phospholipid fatty acid turnover in coordination with lysotransferase enzymes. Additional studies are necessary to fully understand the role of iPLA 2 in lymphocyte proliferative processes.
Finally, the involvement of specific PLA 2 isoforms in the regulation of cell division may be a cell-type specific phenomena. We have shown the 85-kDa PLA 2 to be very important and required for vascular smooth muscle cell proliferation (32) . Exposure of vascular smooth muscle cell to BEL, the iPLA 2 selective inhibitor, had no effect on proliferation (32) . However, in lymphocytes the predominant PLA 2 isoform is the calciumindependent and it is this enzyme which is required for mediating the PL metabolism required to sustain proliferation. Taken together these findings may have interesting implications in terms of defining possible immune cell selective therapeutics directed against iPLA 2 useful as novel immunosuppressive or anti-leukemic agents.
